Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel. The FDA 510(k) clearance allows the company to immediately begin marketing and selling the T2Biothreat Panel in the U.S. market.

Danaher on Tuesday announced that it will provide Cepheid's tuberculosis test to the Global Fund to Fight AIDS, TB, and Malaria, as well as to less-developed countries eligible for Cepheid's Global Access Program, at cost.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

An expert panel led by researchers at the Ohio State University Wrexner Medical Center and College of Medicine has published a set of evidence-based guidelines for genetic testing and counseling for people with amyotrophic lateral sclerosis (ALS).

Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Experts have raised concerns about Quest Diagnostics’ $399 consumer-initiated Alzheimer’s disease test, telling 360Dx that it is unclear whether the product is accurate enough to support its use.

Diagnostic healthcare company New Day Diagnostics has announced the approval of an agreement to acquire Epigenomics to provide accessible and innovative diagnostic solutions.

Natera on Thursday announced a new study within the Phase II I-SPY 2 trial that will evaluate the ability of its Signatera minimal residual disease test to monitor breast cancer patients' response to neoadjuvant therapy.

MGI Tech said on Thursday that it has signed a memorandum of understanding with South Korean life science tools distributor Bio-Medical Science (BMS) to bring its next-generation sequencing products to South Korea.